Characterization of Cannabidiol in Alternative Biological Specimens and Urine, after Consumption of an Oral Capsule

Abstract

Abstract Among the hundred cannabinoids present in cannabis sativa indica, cannabidiol (CBD) is a phytocannabinoid discovered in 1940, which can account for up to 40% of the plant’s extract. Medically, it has been proposed to treat convulsions, inflammation, anxiety and nausea. Contrary to the hallucinogenic ingredient of the plant, delta-9-tetrahydrocannabinol, CBD does not seem to have a sedative effect, which can increase its popularity among users. The identification of CBD in blood and urine has been widely described in the scientific literature for several years. Only few data have been reported regarding CBD identification in alternative specimens, such as oral fluid, sweat, exhaled breath and hair. CBD capsules were purchased in the USA from a grocery store and a green capsule containing 22 mg of CBD was orally administered to a 59-year-old healthy man. Oral fluid was collected over 8 h using the NeoSal™ device. Sweat was collected using PharmCheck™ sweat patch technology over 7 days. Exhaled breath was collected with the ExaBreath® DrugTrap device over 8 h. Beard hair was collected 7 and 14 days after administration. Finally, urine specimens were collected over 48 h in plastic tubes without preservative. CBD was only detected in oral fluid at 15 min, at 20 pg/mL. Increasing concentrations, up to 96 pg/patch of CBD, were detected in the sweat patches. CBD was detected for 45 minutes in exhaled breath (Cmax of 302 pg/filter at 30 min). CBD produced a very low but significant chromatographic signal in beard hair, with concentrations <1 pg/mg. Finally, CBD tested positive in urine after enzymatic hydrolysis with a Cmax at 70 ng/mL, after 6 h.